Dexcom

Leadership transitioned smoothly to 20‑year veteran Jake Leach as CEO on January 1, 2026, following a multiyear succession process. Under his stewardship as COO and President, Dexcom advanced G7 rollout, 15‑Day clearance, AID integrations, Stelo OTC, and Smart Basal.

Offsetting this strong track record, 2025 brought an FDA warning letter tied to quality systems and a Class I software correction of G7 and ONE+ apps, which heightens execution scrutiny. We balance deep domain continuity and a robust product roadmap with the need for demonstrable remediation and sustained quality.